Alaunos Therapeutics, Inc. (NASDAQ:TCRT) Short Interest Update

Alaunos Therapeutics, Inc. (NASDAQ:TCRT) was the recipient of a significant decline in short interest in January. As of January 15th, there was short interest totalling 108,500 shares, a decline of 18.5% from the December 31st total of 133,100 shares. Based on an average daily trading volume, of 24,000 shares, the short-interest ratio is presently 4.5 days. Approximately 7.9% of the shares of the stock are short sold.

Alaunos Therapeutics Stock Down 0.3 %

NASDAQ TCRT traded down $0.01 during trading hours on Thursday, reaching $1.72. 5,150 shares of the company’s stock were exchanged, compared to its average volume of 20,355. The firm has a fifty day moving average of $2.02 and a 200-day moving average of $2.52. Alaunos Therapeutics has a one year low of $1.60 and a one year high of $26.94.

About Alaunos Therapeutics

Alaunos Therapeutics, Inc, a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers.